These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30801741)

  • 21. PK-PD Analysis of Marbofloxacin against
    Lei Z; Liu Q; Yang B; Khaliq H; Cao J; He Q
    Front Pharmacol; 2017; 8():856. PubMed ID: 29209222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, bioavailability and PK/PD relationship of cefquinome for Escherichia coli in Beagle dogs.
    Zhou YF; Zhao DH; Yu Y; Yang X; Shi W; Peng YB; Liu YH
    J Vet Pharmacol Ther; 2015 Dec; 38(6):543-8. PubMed ID: 25776615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tilmicosin- and florfenicol-loaded hydrogenated castor oil-solid lipid nanoparticles to pigs: Combined antibacterial activities and pharmacokinetics.
    Ling Z; Yonghong L; Junfeng L; Li Z; Xianqiang L
    J Vet Pharmacol Ther; 2018 Apr; 41(2):307-313. PubMed ID: 29139136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PK/PD integration and pharmacodynamic cutoff of cefquinome against cow mastitis due to Escherichia coli.
    Xiao X; Chen X; Yan K; Jiang L; Li R; Liu Y; Wang M; Wang Z
    J Vet Pharmacol Ther; 2022 Jan; 45(1):83-91. PubMed ID: 34469000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic-pharmacodynamic modeling of cyadox against Escherichia coli in swine.
    Huang L; Maan MK; Xu D; Bakr Shabbir MA; Dai M; Yuan Z
    Microb Pathog; 2019 Oct; 135():103650. PubMed ID: 31376503
    [No Abstract]   [Full Text] [Related]  

  • 26. The dose regimen formulation of tilmicosin against Lawsonia intracellularis in pigs by pharmacokinetic-pharmacodynamic (PK-PD) model.
    Luo W; Qin H; Chen D; Wu M; Meng K; Zhang A; Pan Y; Qu W; Xie S
    Microb Pathog; 2020 Oct; 147():104389. PubMed ID: 32707311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of florfenicol in healthy and Escherichia coli-infected broiler chickens.
    Shen J; Wu X; Hu D; Jiang H
    Res Vet Sci; 2002 Oct; 73(2):137-40. PubMed ID: 12204631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling.
    Liu X; Yang Q; Fan Y; Du Y; Lei L; Wang D; Liu Y
    BMC Vet Res; 2021 Jun; 17(1):212. PubMed ID: 34107961
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Xiao X; Lan W; Zhao Y; Li R; Liu Y; Liu J; Wang Z
    Front Microbiol; 2020; 11():616685. PubMed ID: 33505384
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks.
    Yu Y; Zhou YF; Sun J; Shi W; Liao XP; Liu YH
    BMC Vet Res; 2017 Feb; 13(1):47. PubMed ID: 28183350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular analysis of florfenicol-resistant Escherichia coli isolates from pigs.
    Blickwede M; Schwarz S
    J Antimicrob Chemother; 2004 Jan; 53(1):58-64. PubMed ID: 14645321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wild-type cutoff for Apramycin against Escherichia coli.
    Yang Y; Xiao T; Li J; Cheng P; Li F; Yu H; Liu R; Muhammad I; Zhang X
    BMC Vet Res; 2020 Aug; 16(1):309. PubMed ID: 32847547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Rubio-Langre S; Aguilar-Sola S; Lorenzutti AM; San Andrés MI; De Lucas JJ; Litterio NJ
    J Vet Pharmacol Ther; 2018 Dec; 41(6):861-870. PubMed ID: 30020535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against
    Somogyi Z; Mag P; Kovács D; Kerek Á; Szabó P; Makrai L; Jerzsele Á
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic/pharmacodynamic evaluation of the efficacy of flumequine in treating colibacillosis in turkeys.
    Ferraresi C; Lucatello L; Meucci V; Intorre L; Grilli G; Piccirillo A; Russo E; Villa R; Montesissa C; Cagnardi P
    Poult Sci; 2013 Dec; 92(12):3158-65. PubMed ID: 24235225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enrofloxacin against Escherichia coli in turkeys: which treatment scheme is effective?
    Cagnardi P; Ferraresi C; Lucatello L; Meucci V; Intorre L; Grilli G; Piccirillo A; Giacomelli M; Montesissa C
    Poult Sci; 2014 Jul; 93(7):1667-74. PubMed ID: 24864295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activity of cyadox against Clostridium perfringens in broilers and a dosage regimen design based on pharmacokinetic-pharmacodynamic modeling.
    Wang F; Mi K; Ahmad I; Xie S; Hussain HI; Yuan Z; Dai M; Huang L
    Microb Pathog; 2020 Apr; 141():103981. PubMed ID: 31962185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PREVALENCE OF SULFONAMIDE AND FLORFENICOL RESISTANCE GENES IN ESCHERICHIA COLI ISOLATED FROM YAKS (BOS GRUNNIENS) AND HERDSMEN IN THE TIBETAN PASTURE.
    Zhang A; Yang Y; Wang H; Lei C; Xu C; Guan Z; Liu B; Huang X; Peng L
    J Wildl Dis; 2015 Jul; 51(3):626-33. PubMed ID: 25973625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing tylosin dosage for co-infection of
    Lee EB; Abbas MA; Park J; Tassew DD; Park SC
    Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro assessment of chloramphenicol and florfenicol as second-line antimicrobial agents in dogs.
    Maaland MG; Mo SS; Schwarz S; Guardabassi L
    J Vet Pharmacol Ther; 2015 Oct; 38(5):443-50. PubMed ID: 25623169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.